Diagnosing and treating rare and orphan diseases remains one of the life science sector’s great challenges. This is compounded by small patient populations, which are difficult to access and lead to significant challenges for the healthcare industry in rare disease management and support of these patient populations. Nagore Fernandez, Ashfield, identifies how rare disease patients require a more personalised approach than those with common conditions, and often these patients extensively self-educate about their condition.